Table 2.
Profile of medication received by patients with heart failure with preserved ejection fraction
| Diuretics | RAS inhibitor | Beta-blocker | MRA | Digoxin | Amiodarone | OAC | NOAC | Statin | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall population | 1710 (79.4) | 1450 (67.3) | 1685 (78.3) | 828 (38.5) | 388 (18.0) | 98 (12.8) | 1104 (59.2) | 79 (4.2) | 1754 (81.5) | ||
| Subgroups | |||||||||||
| Age | |||||||||||
| < 65 years | 183 (52.4) | 240 (68.8) | 273 (78.2) | 100 (28.7) | 40 (11.5) | 8 (11.3) | 99 (39.3) | 9 (3.6) | 314 (90.0) | ||
| 65–80 years | 709 (78.2) | 653 (72.0) | 720 (79.4) | 329 (36.3) | 164 (18.1) | 51 (17.8) | 459 (57.2) | 34 (4.2) | 786 (86.7) | ||
| > 80 years | 816 (91.2) | 555 (62.0) | 691 (77.2) | 399 (44.6) | 183 (20.4) | 39 (9.6) | 545 (67.5) | 36 (4.5) | 653 (73.0) | ||
| p-value | < 0.001 | < 0.001 | 0.534 | < 0.001 | 0.001 | 0.006 | < 0.001 | 0.831 | <0.001 | ||
| Sex | |||||||||||
| Men | 725 (74.2) | 658 (67.3) | 767 (78.5) | 353 (36.1) | 148 (15.1) | 36 (11.9) | 463 (54.4) | 32 (3.8) | 829 (84.9) | ||
| Women | 980 (83.8) | 787 (67.3) | 915 (78.2) | 471 (40.3) | 239 (20.4) | 61 (13.3) | 636 (63.2) | 47 (4.7) | 920 (78.6) | ||
| p-value | < 0.001 | 0.967 | 0.866 | 0.050 | 0.002 | 0.568 | < 0.001 | 0.334 | < 0.001 | ||
| Hypertension | |||||||||||
| With HT | 890 (81.5) | 781 (71.5) | 870 (79.7) | 406 (37.2) | 189 (17.3) | 54 (12.7) | 580 (61.4) | 35 (3.7) | 881 (80.7) | ||
| Without HT | 820 (77.3) | 669 (63.1) | 815 (76.8) | 422 (39.8) | 199 (18.8) | 44 (13.0) | 524 (57.0) | 44 (4.8) | 873 (82.3) | ||
| p-value | 0.016 | < 0.001 | 0.108 | 0.216 | 0.382 | 0.901 | 0.056 | 0.245 | 0.338 | ||
| Atrial fibrillation | |||||||||||
| With AF | 767 (93.3) | 543 (66.1) | 662 (80.5) | 410 (49.9) | 293 (35.6) | 31 (9.1) | 678 (86.3) | 51 (6.5) | 623 (75.8) | ||
| Without AF | 931 (70.9) | 899 (68.4) | 1,010 (76.9) | 410 (31.2) | 90 (6.8) | 64 (15.3) | 415 (39.1) | 28 (2.6) | 1120 (85.2) | ||
| p-value | < 0.001 | 0.257 | 0.045 | < 0.001 | <0.001 | 0.010 | < 0.001 | < 0.001 | <0.001 | ||
| Diabetes mellitus | |||||||||||
| With DM | 567 (87.9) | 445 (69.0) | 509 (78.9) | 267 (41.4) | 123 (19.1) | 27 (11.1) | 342 (60.6) | 18 (3.2) | 560 (86.8) | ||
| Without DM | 1143 (75.8) | 1005 (66.6) | 1176 (78.0) | 561 (37.2) | 265 (17.6) | 71 (13.6) | 762 (55.7) | 61 (4.7) | 1194 (79.2) | ||
| p-value | < 0.001 | 0.287 | 0.632 | 0.067 | 0.408 | 0.323 | 0.488 | 0.134 | < 0.001 | ||
| Congestiona | |||||||||||
| With congestion | 257 (88.0) | 173 (59.2) | 226 (77.4) | 113 (38.7) | 53 (18.2) | 16 (12.1) | 172 (64.4) | 7 (2.6) | 231 (79.1) | ||
| Without congestion | 9689 (72.0) | 937 (69.7) | 1042 (77.5) | 406 (30.2) | 217 (16.1) | 71 (12.7) | 632 (52.9) | 54 (4.5) | 1059 (78.7) | ||
| p-value | < 0.001 | 0.001 | 0.978 | 0.005 | 0.400 | 0.851 | 0.001 | 0.161 | 0.887 | ||
RAS renin-angiotensin system, MRA mineralocorticoid receptor antagonist, OAC oral anticoagulant, NOAC non-vitamin K OAC, HT hypertension, AF atrial fibrillation, DM diabetes mellitus
aIndicated by either peripheral oedema or other signs of a hypervolaemic status